Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clazakizumab · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Clazakizumab Dose 1 | EXPERIMENTAL | Participants will receive clazakizumab subcutaneously (SC) |
| Clazakizumab Dose 2 | EXPERIMENTAL | Participants will receive clazakizumab SC |
| Clazakizumab Dose 3 | EXPERIMENTAL | Participants will receive clazakizumab SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Name | Type | Description |
|---|---|---|
| Clazakizumab | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * hsCRP ≥2 mg/L and ≤15 mg/L at screening * At least one of the following chronic conditions: * Established atherosclerotic cardiovascular disease (ASCVD) * Obesity (body mass index (BMI) ≥30 kg/m2) * Type 2 diabetes * Hypertension * Chronic kidney disease Grade 3 or ...
Clazakizumab is an investigational drug being studied for atherosclerosis in adults with elevated hsCRP who are at increased risk for a cardiovascular event. The study also includes patients with conditions such as cardiovascular disease, obesity, hypertension, type 2 diabetes, and chronic renal insufficiency.
Clazakizumab is a monoclonal antibody, indicated by the -mab suffix in its name. It is being developed as a small molecule modality, though its specific molecular target is not disclosed in the available information.
Clazakizumab is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the stock exchange under the ticker symbol LLY.
Clazakizumab is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 study is designed to evaluate its effects in the target patient population.
Clazakizumab is being studied in a Phase 2 clinical trial with the identifier NCT07783802. This randomized, double-blind, placebo-controlled trial plans to enroll 120 participants and is currently not yet recruiting. The study is being conducted in the United States, Argentina, Japan, and Puerto Rico.
Yes, Clazakizumab is also known as LY5724886. The clinical trial NCT07783802, which studies Clazakizumab, lists LY5724886 as an alternative name for the drug.